Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

ABSTRACT: mTOR inhibitors are frequently used in the treatment of metastatic renal cell cancer (mRCC). mTOR regulates cell growth, proliferation, angiogenesis, and survival, and additionally plays an important role in immune regulation. Since mTOR inhibitors were shown to benefit immunosuppressive r...

Descripción completa

Detalles Bibliográficos
Autores principales: Huijts, Charlotte M., Werter, Inge M., Lougheed, Sinéad M., Goedegebuure, Ruben S., van Herpen, Carla M., Hamberg, Paul, Tascilar, Metin, Haanen, John B., Verheul, Henk M., de Gruijl, Tanja D., van der Vliet, Hans J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394488/
https://www.ncbi.nlm.nih.gov/pubmed/30413837
http://dx.doi.org/10.1007/s00262-018-2248-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394488/
https://www.ncbi.nlm.nih.gov/pubmed/30413837
http://dx.doi.org/10.1007/s00262-018-2248-3

Ejemplares similares